CMB
Director Trades
| Date | Director | Value |
|---|---|---|
| 11/3/25 | C. Bala | $23,185 |
| 11/3/25 | Y. Tseng | $2,345,479 |
| 11/3/25 | E. Waller | $23,185 |
| 11/3/25 | T. Walts | $23,185 |
Company News
Cambium Bio gains US FDA approval for Phase 3 Elate Ocular dry eye disease trial protocol
Cambium Bio (ASX: CMB) has received approval from the US Food and Drug Administration (FDA) for a protocol relating to Phase 3 clinical trials of its Elate Ocular treatment for moderate-to-severe dry eye disease. The approval represents a key milestone in advancing Elate Ocular towards market registration and follows the FDA granting the product fast-track […]
Regeneus and Cambium merge to refine dry eye treatment development
Australian regenerative medicine firm Regeneus (ASX: RGS) and US-headquartered Cambium Medical Technologies (CMT) have completed a merger that will see them combine to further develop a novel biologic treatment for dry eye disease. Regeneus is a Sydney-based company focused on the development of innovative biologics for ophthalmology and tissue repair applications. Cambium Medical is a […]